Bengaluru on high alert after Gauri Lankesh murder; crime caught on CCTV?

Mangaluru, Jul 11: Under the fourth phase of Vande Bharat Mission, the government of India has announced as many as 42 repatriation flights from Saudi Arabia to various Indian destinations including four flights to Karnataka. 

On July 25 an Air India flight will fly from Dammam International Airport to Kempegowda International Airport in Bengaluru.

On July 26 another Air India flight will take off from Dammam and land in Bengaluru and then again it will continue its journey till Mangaluru International Airport. 

On July 27, Air India will operate a flight from Jeddah’s King Abdulaziz International Airport to Bengaluru. 

On July 28, Air India will operate another flight from Jeddah to Mangaluru. It will be the last flight from Saudi to Karnataka under the fourth phase of Vande Bharat Mission.

Kalaburagi, Mar 9: As the International Women's Day was celebrated all across the globe, the Department of Post inaugurated the first-ever all-women-employees operating post office here in Kalaburagi.

"Today, we have declared the Jagat Post Office under the Kalaburagi district as women's post office. From today onwards, women staff is going to work here exclusively," CG Kamble, Assistant Superintendent, Post Office, told media.

One of the employees of the post office inaugurated on Monday said: "We are happy that we can work freely as all the employees here are women. Similarly, the government must also take steps to identify one of the offices in the state as only women employees' office."

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.